BRAF V600E vs cell of origin: what governs LCH?

[1]  F. Ginhoux,et al.  Transcriptomic Landscape of Circulating Mononuclear Phagocytes in Langerhans Cell Histiocytosis at Single-cell Level. , 2021, Blood.

[2]  M. Merad,et al.  BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology , 2020, Nature Medicine.

[3]  N. McGovern,et al.  Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. , 2020, Blood advances.

[4]  C. Bock,et al.  Epigenomics and Single-cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis. , 2019, Cancer discovery.

[5]  A. Idbaih,et al.  Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Rodríguez-Galindo,et al.  Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. , 2019, Blood.

[7]  Ahmet Dogan,et al.  Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms , 2019, Nature.

[8]  M. Merad,et al.  Langerhans‐Cell Histiocytosis , 2018, New England Journal of Medicine.

[9]  M. Merad,et al.  RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions , 2018, The Journal of experimental medicine.

[10]  M. Merad,et al.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2014, The Journal of experimental medicine.